Switching from Biologics to JAK Inhibitors in Atopic Dermatitis: Clinical Data

Author(s):

Raj Chovatiya, MD, PhD,George Han, MD, PhD

Key Takeaways

Abrocitinib and upadacitinib provide alternative mechanisms for disease control in patients previously treated with dupilumab.
JAK inhibitors may be considered when patients experience inadequate response, loss of efficacy, or adverse effects with dupilumab.
Individualized treatment decisions should consider disease severity, treatment history, and JAK inhibitor-associated risk factors.

Medical experts discuss disease control with abrocitinib or upadacitinib in patients previously taking dupilumab and explain the circumstances under which they would switch a patient to a JAK inhibitor.

EP: 1.JAK Inhibitors and Pathophysiology of Atopic Dermatitis

EP: 2.Oral JAK inhibitors and Their Use for Treatment of Atopic Dermatitis

EP: 3.Oral JAK Inhibitor Use in Atopic Dermatitis: Screening and Monitoring Patients

EP: 4.Long-term Safety Data for JAK Inhibitors in Atopic Dermatitis

EP: 5.Utilizing Long-Term Atopic Dermatitis Data in Clinical Practice

EP: 6.Data on Early Itch Relief with JAK Inhibitors in Atopic Dermatitis

EP: 7.Speed of Itch Relief in Atopic Dermatitis

EP: 8.Systemic Treatments and Switching Therapy in Atopic Dermatitis

EP: 9.Treatment Expectations and Patient Conversations in Atopic Dermatitis

Now Viewing

EP: 10.Switching from Biologics to JAK Inhibitors in Atopic Dermatitis: Clinical Data

EP: 11.Treatment Breaks and Rescue Treatments in Atopic Dermatitis

EP: 12.Switching patients to JAK Inhibitors in Atopic Dermatitis in Clinical Practice

EP: 13.Treatment Flexibility While on Abrocitinib in Atopic Dermatitis (JADE REGIMEN)

EP: 14.Future Outlook for Atopic Dermatitis Treatments

Video content above is prompted by the following:

Can you discuss disease control with abrocitinib or upadacitinib in patients previously treated with dupilumab?
When would you switch a patient to a JAK inhibitor?